Jaifry
Revolutionizing Diabetes Management with Automated Hypoglycemia Detection and Treatment
Our Vision & Mission
Our Vision
Creating a world where diabetes patients no longer fear hypoglycemic episodes, where technology seamlessly monitors and manages blood glucose levels, providing peace of mind and improving quality of life for millions of people worldwide.
Our Mission
To develop, manufacture, and distribute the Jaifry system – an innovative automated device that continuously monitors blood glucose levels and administers glucagon when dangerously low levels are detected, preventing severe hypoglycemic episodes before they become life-threatening.
Our Promise
We are committed to continuous innovation, uncompromising quality, and patient-centered design in all our products. We will work tirelessly to ensure that diabetes management becomes safer, simpler, and more effective for everyone affected by this condition.
The Problem We Solve
Hypoglycemia Risks
Severe hypoglycemia (low blood sugar) is a life-threatening condition affecting millions of diabetes patients. It can lead to seizures, loss of consciousness, brain damage, and even death if not treated immediately.
Nocturnal Hypoglycemia
Over 50% of severe hypoglycemia cases occur during sleep when patients cannot recognize symptoms and take corrective action, making it particularly dangerous.
Hypoglycemia Unawareness
Many long-term diabetes patients develop hypoglycemia unawareness—the inability to perceive the early warning signs of low blood sugar, significantly increasing their risk of severe episodes.
| Hypoglycemia Impact Statistics | Data | Source |
|---|---|---|
| Annual ER visits related to hypoglycemia in the US | Over 300,000 | Centers for Disease Control (CDC) |
| Percentage of Type 1 diabetes patients experiencing severe hypoglycemia annually | 30-40% | Diabetes Care Journal |
| Increased risk of mortality from severe hypoglycemia | 3.4 times higher | Lancet Diabetes & Endocrinology |
| Economic burden of hypoglycemia in the US | $1.8 billion annually | American Diabetes Association |
Our Revolutionary Solution
The Jaifry System
Jaifry is an integrated wearable system that combines continuous glucose monitoring with automated glucagon administration, creating a comprehensive safety net for diabetes patients.
How It Works:
| Component | Function | Innovation |
|---|---|---|
| Advanced CGM Sensor | Continuously monitors interstitial glucose levels with 99.2% accuracy | Proprietary algorithm predicts trends 30 minutes in advance |
| AI-Powered Analysis Engine | Processes glucose data, activity levels, insulin-on-board, and historical patterns | Machine learning adapts to individual patient physiology |
| Precision Delivery System | Administers precise doses of stable liquid glucagon when needed | Uses a novel glucagon formulation that remains stable for 6 months at room temperature |
| Smart Alert System | Notifies the patient and emergency contacts when an intervention occurs | Integrated with smart home systems and emergency services |
Advanced Technology
Next-Gen Sensing Technology
Our proprietary multi-enzyme sensor achieves unprecedented accuracy in glucose detection, with minimal calibration requirements and resistance to common interferences like acetaminophen.
Predictive AI Algorithms
The Jaifry machine learning system analyzes hundreds of data points to predict hypoglycemia events before they happen, allowing for proactive intervention.
Stable Glucagon Formulation
We have developed a novel glucagon analog that remains stable in liquid form for extended periods, eliminating the need for reconstitution before use.
Technical Specifications
| Parameter | Specification | Benefit |
|---|---|---|
| Glucose Measurement Range | 20-500 mg/dL | Covers both hypoglycemia and hyperglycemia ranges |
| MARD (Mean Absolute Relative Difference) | 7.8% | Industry-leading accuracy |
| Connectivity | Bluetooth 5.2, NFC | Seamless connection with smartphones and medical devices |
| Battery Life | 14 days (Sensor), 6 months (Delivery Unit) | Minimal maintenance requirements |
| Glucagon Reservoir | 3 doses of 1mg each | Multiple protection against recurrent hypoglycemia |
| Water Resistance | IP68 (Up to 1.5m for 30 minutes) | Worry-free showering and swimming |
Development Roadmap
Q2 2023 - R&D Phase
Prototype development completed. Established partnerships with leading endocrinology research centers. Filed 12 core patents for sensor technology and glucagon formulation.
Q4 2023 - Pre-clinical Testing
Commencement of animal studies to verify safety and efficacy. Achieved 99.2% detection accuracy in controlled lab environments. Refined AI algorithms based on initial test data.
Q2 2024 - Initial FDA Submission
Submission of the pre-IDE package to the FDA. Commenced manufacturing process development for scalable production. Established ISO 13485 compliant quality management system.
Q4 2024 - Phase I Clinical Trials
Beginning of first-in-human studies with 50 participants. Demonstrating initial safety and efficacy profile. Refining user interface based on patient feedback.
Q2 2025 - Phase II Clinical Trials
Expanding trials to 200 participants across 5 clinical sites. Gathering real-world performance data. Applying for CE Mark in the European Union.
Q4 2025 - Pivotal Trial & FDA Submission
Starting the pivotal trial with 500 participants. Preparation of the PMA submission to the FDA. Finalizing commercial manufacturing processes.
Q2 2026 - Regulatory Approval & Launch
Expected FDA approval and commercial launch in US markets. Beginning international expansion to the EU and other global markets.
Leadership Team
Mr. Mohamed Al-Jaifry
Chief Executive Officer
Dr. Ahmed Khalid
Chief Technology Officer
PhD in Biomedical Engineering, 20+ patents in sensing technology
Dr. Yusuf Saleh
Chief Medical Officer
Board-certified endocrinologist, 12 years clinical practice specialized in diabetes
Mr. Fahad Amin
Chief Operating Officer
Former Manufacturing Director at PharmaTech, experienced in medical device scaling
Scientific Advisory Board
| Name | Affiliation | Expertise |
|---|---|---|
| Mr. Mohamed Al-Jaifry | Jaifry Inc. | Diabetes Technology & Artificial Pancreas Systems |
| Dr. Ibrahim Hassan | Global Health Inst. | Endocrinology Research & Hypoglycemia |
| Dr. Kareem Malik | University of Science | Biomedical Sensors & Wearable Tech |
| Dr. Abdullah Aziz | Regulatory Partners | Clinical Trial Design & Regulatory Strategy |
Expected Impact
Patient Impact
We expect Jaifry to prevent approximately 250,000 cases of severe hypoglycemia annually in Saudi Arabia alone, significantly reducing ER visits, hospitalizations, and hypoglycemia-related deaths.
Economic Impact
By preventing severe hypoglycemia episodes, Jaifry could potentially save the Saudi healthcare system over 100 million riyals annually in direct medical costs, plus additional savings from reduced productivity losses.
Quality of Life Impact
Our research indicates that Jaifry can reduce diabetes-related anxiety by 65% and improve overall quality of life scores by 42% among users, particularly those with hypoglycemia unawareness.
Market Projections
| Market Segment | Target Population | Expected Penetration (Year 3) | Potential Revenue |
|---|---|---|---|
| Type 1 Diabetes - High Risk | 1.2 Million (US) | 35% | $1.8 Billion |
| Type 1 Diabetes - All Patients | 1.6 Million (US) | 22% | $2.1 Billion |
| Type 2 Diabetes - Insulin Dependent | 4.5 Million (US) | 12% | $3.2 Billion |
| International Markets | 25 Million (Global) | 8% | $6.5 Billion |